tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

NGENF Stock Latest News

NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment
Company AnnouncementsNervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment
10d ago
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment
PremiumCompany Announcements
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment
10d ago
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development
PremiumCompany Announcements
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development
15d ago
NervGen Pharma Secures $10 Million to Propel Nasdaq Listing and NVG-291 Development
PremiumCompany Announcements
NervGen Pharma Secures $10 Million to Propel Nasdaq Listing and NVG-291 Development
16d ago
NGENF Earnings this Week: How Will it Perform?
PremiumPre-Earnings
NGENF Earnings this Week: How Will it Perform?
23d ago
Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment
PremiumCompany AnnouncementsNervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment
1M ago
NGENF
NervGen Pharma Reports Breakthrough in Spinal Cord Injury Treatment
Premium
Company Announcements
NervGen Pharma Reports Breakthrough in Spinal Cord Injury Treatment
3M ago
NervGen Pharma’s NVG-291-R Shows Promising Preclinical Results in Nerve Repair
Premium
Company Announcements
NervGen Pharma’s NVG-291-R Shows Promising Preclinical Results in Nerve Repair
4M ago
NervGen Pharma Announces Leadership Change Amid Positive Trial Results
PremiumCompany Announcements
NervGen Pharma Announces Leadership Change Amid Positive Trial Results
5M ago
NervGen Pharma Updates on Equity Program and Stock Options
PremiumCompany Announcements
NervGen Pharma Updates on Equity Program and Stock Options
5M ago
NervGen Pharma Strengthens Leadership Amid Positive Trial Results
PremiumCompany Announcements
NervGen Pharma Strengthens Leadership Amid Positive Trial Results
5M ago
NervGen Pharma Announces Leadership Transition Amid NVG-291 Advancements
PremiumCompany Announcements
NervGen Pharma Announces Leadership Transition Amid NVG-291 Advancements
5M ago
NervGen Pharma Appoints Dr. Randall Kaye as Chief Medical Advisor
PremiumCompany AnnouncementsNervGen Pharma Appoints Dr. Randall Kaye as Chief Medical Advisor
6M ago
NervGen Pharma price target raised to C$6 from C$4.50 at Raymond James
Premium
The Fly
NervGen Pharma price target raised to C$6 from C$4.50 at Raymond James
6M ago
NervGen Pharma price target raised to C$5 from C$4.50 at Stifel
Premium
The Fly
NervGen Pharma price target raised to C$5 from C$4.50 at Stifel
6M ago
NervGen Pharma Announces Breakthrough Results in Spinal Cord Injury Treatment Trial
PremiumCompany Announcements
NervGen Pharma Announces Breakthrough Results in Spinal Cord Injury Treatment Trial
6M ago
NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291
PremiumThe Fly
NervGen reports topline data from chronic cohort of Phase 1b/2a trial of NVG-291
6M ago
NervGen Pharma to Present Promising NVG-291 Study Results at ASIA Meeting
PremiumCompany Announcements
NervGen Pharma to Present Promising NVG-291 Study Results at ASIA Meeting
7M ago
NervGen Pharma Awards Stock Options to Directors and Employees
PremiumCompany Announcements
NervGen Pharma Awards Stock Options to Directors and Employees
7M ago
NervGen Pharma Reports Q1 2025 Financial Results and Advances NVG-291 Clinical Development
PremiumCompany AnnouncementsNervGen Pharma Reports Q1 2025 Financial Results and Advances NVG-291 Clinical Development
7M ago
NervGen Pharma Secures Shareholder Support at AGM
Premium
Company Announcements
NervGen Pharma Secures Shareholder Support at AGM
7M ago
NervGen Pharma to Present at 2025 Healthcare Investor Conference
Premium
Company Announcements
NervGen Pharma to Present at 2025 Healthcare Investor Conference
8M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >